Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Intra-cellular Thera74, Inc. (ITCI)
since 2013 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Intra-cellular Thera74, Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 1567514.
Total stock buying since 2013: $37,228,078.
Total stock sales since 2013: $221,630,438.
Total stock option exercises since 2013: $38,819,239.
Table 3. Detailed insider trading at Intra-cellular Thera74, Inc. (ITCI) , Part 3
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2019-01-07 | Halstead Michael (EVP and General Counsel) | Sale | 3,108 | 12.42 | 38,601 |
| 2019-01-04 | Mates Sharon (Chairman, President & CEO) | Sale | 45,598 | 11.60 | 528,936 |
| 2019-01-04 | Mates Sharon (Chairman, President & CEO) | Option Ex | 6,604 | .00 | 0 |
| 2019-01-04 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 21,458 | 11.63 | 249,556 |
| 2019-01-04 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 3,108 | .00 | 0 |
| 2019-01-04 | Vanover Kimberly E. (SVP, Early Stage Clinical Dev.) | Sale | 9,564 | 11.59 | 110,846 |
| 2019-01-04 | Vanover Kimberly E. (SVP, Early Stage Clinical Dev.) | Option Ex | 1,554 | .00 | 0 |
| 2019-01-04 | Halstead Michael (EVP and General Counsel) | Sale | 21,458 | 11.57 | 248,269 |
| 2019-01-04 | Halstead Michael (EVP and General Counsel) | Option Ex | 3,108 | .00 | 0 |
| 2019-01-04 | Davis Robert E (SVP, Chief Scientific Officer) | Sale | 9,564 | 11.56 | 110,607 |
| 2019-01-03 | Mates Sharon (Chairman, President & CEO) | Option Ex | 45,598 | .00 | 0 |
| 2019-01-03 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 21,458 | .00 | 0 |
| 2019-01-03 | Vanover Kimberly E. (SVP, Early Stage Clinical Dev.) | Option Ex | 18,809 | .00 | 0 |
| 2019-01-03 | Halstead Michael (EVP and General Counsel) | Option Ex | 21,458 | .00 | 0 |
| 2019-01-03 | Davis Robert E (SVP, Chief Scientific Officer) | Option Ex | 18,809 | .00 | 0 |
| 2019-01-02 | Mates Sharon (Chairman, President & CEO) | Sale | 17,478 | 11.09 | 193,831 |
| 2019-01-02 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 7,807 | 11.09 | 86,579 |
| 2019-01-02 | Vanover Kimberly E. (SVP, Early Stage Clinical Dev.) | Sale | 4,834 | 11.10 | 53,657 |
| 2019-01-02 | Halstead Michael (EVP and General Counsel) | Sale | 7,807 | 11.09 | 86,579 |
| 2019-01-02 | Davis Robert E (SVP, Chief Scientific Officer) | Sale | 4,834 | 11.11 | 53,705 |
| 2018-12-10 | Mates Sharon (Chairman, President & CEO) | Option Ex | 50,000 | 1.50 | 75,000 |
| 2018-12-06 | Davis Robert E (SVP, Chief Scientific Officer) | Sale | 899 | 13.53 | 12,163 |
| 2018-12-04 | Davis Robert E (SVP, Chief Scientific Officer) | Option Ex | 1,758 | .00 | 0 |
| 2018-11-12 | Marcus Joel S (Director) | Sale | 7,000 | 17.94 | 125,580 |
| 2018-11-09 | Marcus Joel S (Director) | Sale | 25,000 | 18.24 | 455,999 |
| 2018-10-22 | Lerner Richard A (Director) | Option Ex | 12,500 | 1.50 | 18,750 |
| 2018-02-16 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 16,319 | 20.01 | 326,543 |
| 2018-02-15 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 33,381 | 20.03 | 668,621 |
| 2018-01-22 | Halstead Michael (SVP and General Counsel) | Sale | 25,500 | 18.03 | 459,765 |
| 2018-01-08 | Mates Sharon (Chairman, President & CEO) | Sale | 6,604 | 17.48 | 115,437 |
| 2018-01-08 | Vanover Kimberly E. (SVP, Clinical Development) | Sale | 772 | 17.46 | 13,479 |
| 2018-01-05 | Mates Sharon (Chairman, President & CEO) | Sale | 11,257 | 17.08 | 192,269 |
| 2018-01-05 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 1,870 | 17.49 | 32,706 |
| 2018-01-05 | Vanover Kimberly E. (SVP, Clinical Development) | Sale | 1,185 | 17.37 | 20,583 |
| 2018-01-05 | Halstead Michael (SVP and General Counsel) | Sale | 1,560 | 17.49 | 27,284 |
| 2018-01-04 | Mates Sharon (Chairman, President & CEO) | Option Ex | 6,604 | .00 | 0 |
| 2018-01-04 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 3,192 | 15.67 | 50,018 |
| 2018-01-04 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 3,108 | .00 | 0 |
| 2018-01-04 | Vanover Kimberly E. (SVP, Clinical Development) | Option Ex | 1,554 | .00 | 0 |
| 2018-01-04 | Halstead Michael (SVP and General Counsel) | Sale | 2,660 | 15.75 | 41,895 |
| 2018-01-04 | Halstead Michael (SVP and General Counsel) | Option Ex | 3,108 | .00 | 0 |
| 2018-01-04 | Davis Robert E (SVP, Chief Scientific Officer) | Sale | 1,115 | 15.60 | 17,394 |
| 2018-01-03 | Mates Sharon (Chairman, President & CEO) | Option Ex | 11,257 | .00 | 0 |
| 2018-01-03 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 5,297 | .00 | 0 |
| 2018-01-03 | Vanover Kimberly E. (SVP, Clinical Development) | Option Ex | 2,648 | .00 | 0 |
| 2018-01-03 | Halstead Michael (SVP and General Counsel) | Option Ex | 5,297 | .00 | 0 |
| 2018-01-03 | Davis Robert E (SVP, Chief Scientific Officer) | Option Ex | 2,648 | .00 | 0 |
| 2017-12-29 | Lerner Richard A (Director) | Buy | 949 | 14.48 | 13,741 |
| 2017-12-29 | Van Nostrand Robert L (Director) | Buy | 345 | 14.48 | 4,995 |
| 2017-12-29 | Riggs Rory B (Director) | Buy | 1,001 | 14.48 | 14,494 |
| 2017-12-11 | Lerner Richard A (Director) | Sale | 7,000 | 15.09 | 105,630 |
| 2017-12-11 | Lerner Richard A (Director) | Option Ex | 12,500 | 1.50 | 18,750 |
| 2017-12-05 | Davis Robert E (SVP, Chief Scientific Officer) | Sale | 650 | 15.00 | 9,750 |
| 2017-12-04 | Davis Robert E (SVP, Chief Scientific Officer) | Option Ex | 1,757 | .00 | 0 |
| 2017-11-22 | Alafi Christopher D (Director) | Buy | 10,000 | 15.55 | 155,500 |
| 2017-10-30 | Mates Sharon (Chairman, President & CEO) | Sale | 18,750 | 15.75 | 295,312 |
| 2017-10-30 | Mates Sharon (Chairman, President & CEO) | Option Ex | 18,750 | 1.50 | 28,125 |
| 2017-10-02 | Alafi Christopher D (Director) | Buy | 258,065 | 15.50 | 4,000,007 |
| 2017-10-02 | Alafi Capital Co Llc (10% Owner) | Buy | 258,065 | 15.50 | 4,000,007 |
| 2017-10-02 | Alafi Moshe (10% Owner) | Buy | 258,065 | 15.50 | 4,000,007 |
| 2017-01-26 | Marcus Joel S (Director) | Option Ex | 95,000 | 2.55 | 242,155 |
| 2017-01-05 | Mates Sharon (Chairman, President & CEO) | Sale | 4,081 | 16.55 | 67,540 |
| 2017-01-05 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 1,918 | 16.58 | 31,800 |
| 2017-01-05 | Vanover Kimberly E. (SVP, Clinical Development) | Sale | 800 | 16.59 | 13,272 |
| 2017-01-05 | Halstead Michael (SVP and General Counsel) | Sale | 1,601 | 16.55 | 26,496 |
| 2017-01-04 | Mates Sharon (Chairman, President & CEO) | Option Ex | 6,603 | .00 | 0 |
| 2017-01-04 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 3,107 | .00 | 0 |
| 2017-01-04 | Vanover Kimberly E. (SVP, Clinical Development) | Option Ex | 1,553 | .00 | 0 |
| 2017-01-04 | Halstead Michael (SVP and General Counsel) | Option Ex | 3,107 | .00 | 0 |
| 2016-12-15 | Vanover Kimberly E. (SVP, Clinical Development) | Sale | 9,375 | 15.24 | 142,921 |
| 2016-12-15 | Vanover Kimberly E. (SVP, Clinical Development) | Option Ex | 18,750 | 1.45 | 27,243 |
| 2016-12-07 | Alafi Christopher D (Director) | Buy | 20,826 | 16.14 | 336,048 |
| 2016-12-07 | Alafi Capital Co Llc (10% Owner) | Buy | 20,826 | 16.14 | 336,048 |
| 2016-12-07 | Alafi Moshe (10% Owner) | Buy | 20,826 | 16.14 | 336,048 |
| 2016-12-06 | Alafi Christopher D (Director) | Buy | 44,174 | 16.33 | 721,449 |
| 2016-12-06 | Alafi Capital Co Llc (10% Owner) | Buy | 44,174 | 16.33 | 721,449 |
| 2016-12-06 | Alafi Moshe (10% Owner) | Buy | 44,174 | 16.33 | 721,449 |
| 2016-12-04 | Davis Robert E (SVP, Chief Scientific Officer) | Option Ex | 1,757 | .00 | 0 |
| 2016-11-14 | Alafi Christopher D (Director) | Buy | 34,000 | 14.50 | 492,966 |
| 2016-11-14 | Alafi Capital Co Llc (10% Owner) | Buy | 34,000 | 14.50 | 492,966 |
| 2016-11-14 | Alafi Moshe (10% Owner) | Buy | 34,000 | 14.50 | 492,966 |
| 2016-02-18 | Lerner Richard A (Director) | Option Ex | 10,000 | 1.36 | 13,600 |
| 2015-12-15 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 22,500 | 51.97 | 1,169,212 |
| 2015-12-15 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 35,000 | 1.45 | 50,855 |
| 2015-12-14 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 22,500 | 51.36 | 1,155,667 |
| 2015-12-14 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 7,500 | .60 | 4,500 |
| 2015-12-11 | Mates Sharon (Chairman, President & CEO) | Sale | 51,500 | 54.29 | 2,796,089 |
| 2015-12-11 | Mates Sharon (Chairman, President & CEO) | Option Ex | 68,750 | 1.15 | 79,268 |
| 2015-12-08 | Marcus Joel S (Director) | Sale | 22,700 | 54.80 | 1,243,960 |
| 2015-12-07 | Marcus Joel S (Director) | Sale | 40,000 | 52.97 | 2,118,600 |
| 2015-12-04 | Marcus Joel S (Director) | Sale | 30,000 | 55.96 | 1,678,800 |
| 2015-11-24 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 5,000 | 55.00 | 275,000 |
| 2015-11-24 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 5,000 | .60 | 3,000 |
| 2015-09-09 | Fienberg Allen A. (VP of Business Development) | Option Ex | 12,500 | 1.36 | 17,000 |
| 2015-08-21 | Fienberg Allen A. (VP of Business Development) | Sale | 200 | 30.30 | 6,060 |
| 2015-08-19 | Fienberg Allen A. (VP of Business Development) | Sale | 10,000 | 30.30 | 303,000 |
| 2015-06-08 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 25,000 | 26.84 | 671,000 |
| 2015-05-19 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Option Ex | 47,500 | 1.24 | 58,900 |
| 2015-03-31 | Fienberg Allen A. (VP of Business Development) | Option Ex | 12,500 | .60 | 7,500 |
| 2015-03-31 | Marcus Joel S (Director) | Option Ex | 15,000 | 1.16 | 17,400 |
| 2015-03-11 | Sosland Morton I. (10% Owner) | Buy | 250,000 | 24.00 | 6,000,000 |
| 2015-01-14 | Fienberg Allen A. (VP of Business Development) | Sale | 5,000 | 19.00 | 95,000 |
| 2014-12-09 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 11,535 | 16.52 | 190,558 |
| 2014-12-08 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 10,965 | 16.91 | 185,418 |
| 2014-12-02 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 37,200 | .50 | 18,600 |
| 2014-12-01 | Alafi Christopher D (Director) | Buy | 1,422 | 14.75 | 20,974 |
| 2014-12-01 | Alafi Capital Co Llc (10% Owner) | Buy | 1,422 | 14.75 | 20,974 |
| 2014-12-01 | Alafi Moshe (10% Owner) | Buy | 1,422 | 14.75 | 20,974 |
| 2014-11-28 | Mates Sharon (Chairman, President & CEO) | Sale | 35,000 | 14.75 | 516,250 |
| 2014-11-28 | Alafi Christopher D (Director) | Buy | 35,000 | 14.75 | 516,250 |
| 2014-11-28 | Alafi Capital Co Llc (10% Owner) | Buy | 35,000 | 14.75 | 516,250 |
| 2014-11-28 | Alafi Moshe (10% Owner) | Buy | 35,000 | 14.75 | 516,250 |
| 2014-11-25 | Mates Sharon (Chairman, President & CEO) | Option Ex | 50,000 | .50 | 25,000 |
| 2014-11-19 | Alafi Christopher D (Director) | Buy | 1,034 | 14.25 | 14,734 |
| 2014-11-19 | Alafi Capital Co Llc (10% Owner) | Buy | 1,034 | 14.25 | 14,734 |
| 2014-11-19 | Alafi Moshe (10% Owner) | Buy | 1,034 | 14.25 | 14,734 |
| 2014-11-18 | Alafi Christopher D (Director) | Buy | 3,531 | 14.23 | 50,246 |
| 2014-11-18 | Alafi Capital Co Llc (10% Owner) | Buy | 3,531 | 14.23 | 50,246 |
| 2014-11-18 | Alafi Moshe (10% Owner) | Buy | 3,531 | 14.23 | 50,246 |
| 2014-11-14 | Alafi Christopher D (Director) | Buy | 133 | 15.07 | 2,004 |
| 2014-11-14 | Alafi Capital Co Llc (10% Owner) | Buy | 133 | 15.07 | 2,004 |
| 2014-11-14 | Alafi Moshe (10% Owner) | Buy | 133 | 15.07 | 2,004 |
| 2014-11-13 | Alafi Christopher D (Director) | Buy | 2,200 | 15.12 | 33,264 |
| 2014-11-13 | Alafi Capital Co Llc (10% Owner) | Buy | 2,200 | 15.12 | 33,264 |
| 2014-11-13 | Alafi Moshe (10% Owner) | Buy | 2,200 | 15.12 | 33,264 |
| 2014-11-12 | Alafi Christopher D (Director) | Buy | 5,000 | 15.23 | 76,150 |
| 2014-11-12 | Alafi Capital Co Llc (10% Owner) | Buy | 5,000 | 15.23 | 76,150 |
| 2014-11-12 | Alafi Moshe (10% Owner) | Buy | 5,000 | 15.23 | 76,150 |
| 2014-11-11 | Alafi Christopher D (Director) | Buy | 5,000 | 15.55 | 77,750 |
| 2014-11-11 | Alafi Capital Co Llc (10% Owner) | Buy | 5,000 | 15.55 | 77,750 |
| 2014-11-11 | Alafi Moshe (10% Owner) | Buy | 5,000 | 15.55 | 77,750 |
| 2014-11-06 | Halstead Michael (SVP and General Counsel) | Buy | 13,000 | 15.47 | 201,110 |
| 2014-11-05 | Halstead Michael (SVP and General Counsel) | Buy | 7,000 | 15.21 | 106,470 |
| 2014-10-16 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 5,152 | 15.00 | 77,280 |
| 2014-10-15 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 2,004 | 15.00 | 30,060 |
| 2014-10-13 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 1,600 | 15.00 | 24,000 |
| 2014-10-08 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 4,745 | 15.00 | 71,175 |
| 2014-10-06 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 636 | 15.00 | 9,540 |
| 2014-10-03 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 15,863 | 15.00 | 237,945 |
| 2014-09-15 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 5,000 | 15.00 | 75,000 |
| 2014-09-08 | Hineline Lawrence J. (VP of Finance CFO) | Sale | 300 | 15.00 | 4,500 |
| 2014-09-08 | Hineline Lawrence J. (VP of Finance CFO) | Option Ex | 300 | .50 | 150 |
| 2014-07-21 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Option Ex | 37,500 | .50 | 18,750 |
| 2014-06-19 | Alafi Moshe (10% Owner) | Sale | 15,742 | 6.35 | 100,008 |
| 2014-05-28 | Fienberg Allen A. (VP of Business Development) | Option Ex | 37,500 | .50 | 18,750 |
| 2014-05-27 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 5,000 | 15.00 | 75,000 |
| 2014-05-22 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Sale | 6,000 | 14.99 | 89,970 |
| 2014-02-05 | Riggs Rory B (Director) | Buy | 28,571 | 17.50 | 499,992 |
| 2013-12-16 | Wennogle Lawrence P. (Vice President, Drug Discovery) | Option Ex | 12,500 | .30 | 3,750 |
Insider trading activities including stock purchases, stock sales, and option exercises
of ITCI listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Intra-cellular Thera74, Inc. (symbol ITCI,
CIK number 1567514) see
the Securities and Exchange Commission (SEC) website.